Articles from Atom Therapeutics Co., Ltd

Atom Therapeutics, a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, announced today Roy J. Wu, MBA, Senior Vice President for Global Business Development, will present a corporate update and clinical data for the company’s lead small molecule drugs at the BIO International Convention 2026, June 22-25, in San Diego.

Atom Therapeutics, a clinical stage biotechnology company developing best-in-class treatments for inflammatory and metabolic diseases, today announced FDA approval of a Phase II clinical trial application of ABP-745, a novel anti-inflammatory agent for atherosclerosis. The company has launched a multi-regional Phase II trial globally.

Atom Therapeutics, a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, announced today it will present two abstracts detailing positive clinical trial data for the company’s two lead drugs, lingdolinurad (ABP-671) for chronic gout and ABP-745 for acute gout flares, at the American College of Rheumatology’s ACR Convergence 2025, October 24 – 29, 2025, in Chicago.

Atom Therapeutics Co., Ltd, a clinical stage biotechnology company developing best-in-class treatments for metabolic and inflammatory diseases, announced today its global Phase 2b/3 clinical trial of lingdolinurad (ABP-671), a novel orally administered URAT1 inhibitor, achieved its primary endpoint with significant efficacy in lowering serum uric acid (sUA) levels and demonstrated good safety and tolerability in treatment of patients with chronic gout.